Pfizer and BioNTech’s mRNA-based vaccine candidate, BNT162b2 against SARS-CoV-2, has demonstrated efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on interim efficacy analysis by an independent Data Monitoring Committee (DMC) from the Phase III trial. After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussi...